EC Number   |
Inhibitors |
Structure |
|---|
   2.3.2.26 | 4-[[(3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino]methyl]-N-(pyridin-4-yl)benzamide |
compound exhibits remarkable anticancer activity with tumor growth inhibition values of 98.3% and 100% at 25 mg/kg and 50 mg/kg orally daily, respectively, against human RPMI-8226 multiple myeloma xenograft. Treatment with the compound also shows a decrease of Itch level in human RPMI-8226 multiple myeloma cells |
 |
| 2.3.2.26 | Calmodulin |
UBE3B interacts with calmodulin via its N-terminal isoleucine-glutamine motif. Deletion of the motif (amino acids 29-58) results in loss of calmodulin binding and a significant increase in the in vitro ubiquitylation activity of UBE3B. Changes in calcium levels in vitro disrupt the calmodulin-UBE3B interaction |
  |
| 2.3.2.26 | chlorpromazine |
minimum inhibitory concentration is 0.3 mM |
|
| 2.3.2.26 | chlorprothixene |
minimum inhibitory concentration is 0.3 mM |
|
| 2.3.2.26 | clomipramine |
antidepressant drug, specifically blocks isoform ITCH auto-ubiquitylation, as well as p73 ubiquitylation. Treating a panel of breast, prostate and bladder cancer cell lines with clomipramine, or its homologs, leads to reduced cancer cell growth, and synergize with gemcitabine or mitomycin in killing cancer cells by blocking autophagy. Minimum inhibitory concentration is 0.3 mM |
|
| 2.3.2.26 | more |
autoinhibition mechanism of domains C2-HECT is not observed in isoform Smurf1 |
|
| 2.3.2.26 | N-acetylphenylalanylamide |
i.e. Phe-823 mimic, acts as a noncompetitive inhibitor of polyubiquitin chain elongation by destabilizing the active trimer |
|
| 2.3.2.26 | norclomipramine |
minimum inhibitory concentration is 0.3 mM |
|
